A phase Ib, open‐label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end‐stage renal disease

Abstract

The endeavor to study desensitization in kidney transplantation has not been matched by an effort to investigate strategies to prevent sensitization. In this study (NCT02437422), we investigated the safety, impact on sensitization, and pharmacokinetics of SANGUINATE (SG), a hemoglobin-based oxygen carrier, as a potential alternative to packed red blood cells (PRBC) in transplant candidates with end-stage renal disease (ESRD). Ten ESRD subjects meeting inclusion/exclusion (I/E) criteria were planned to receive three weekly infusions of SG (320 mg/kg). The study was stopped after five subjects were enrolled, and their data were analyzed after completing a follow-up period of 90 days. Two subjects had elevated troponin I levels in setting of SG infusion, one of which was interpreted as a non-ST elevation myocardial infarction. All other adverse events were transient. SG pharmacokinetic analysis showed mean (SD) C max , T max , AUC, and half-life of 4.39 (0.69) mg/mL, 2.42 (0.91) hours, 171.86 (52.35) mg h/mL, and 40.60 (11.96) hours, respectively. None of the subjects developed new anti-HLA antibodies following SG infusion and throughout the study period. In conclusion, SG is a potential alternative to PRBCs in ESRD patients considered for kidney transplantation as it was not associated with humoral sensitization. Larger studies in highly sensitized patients are required to further evaluate for potential safety signals. K E Y W O R D S

Industrially Compatible Transfusable iPSC-Derived RBCs: Progress, Challenges and Prospective Solutions

“…In 2007, a novel HBOC with platelet-like activity, made by crosslinking hemoglobin with fibrinogen to polyhemoglobin-fibrinogen, showed favorable results in coagulation studies in vitro and in vivo and proceeded into phase III trials [ 33 ]. In 2018, a phase Ib, open-label, single arm study to assess another HBOC, SANGUINATE (SG), in patients with end-stage renal disease resulted in transient adverse events with no immune rejection throughout the study [ 34 ]. While several PFCs and HBOCs have found success in clinical trials, an emerging shift of focus towards stem cells for cultured RBCs took place.…”

Reporter Cell Assessment of TLR4-Induced NF-κB Responses to Cell-Free Hemoglobin and the Influence of Biliverdin

“…Hypothetically, these data may reveal a species-dependent restriction in Hb and TLR4 interactions with this ligand, and could potentially represent an evolutionarily-conserved mechanism in DAMP recognition. Indeed, a therapeutic RBC substitute, Sanguinate TM (PEGylated carboxyhemoglobin bovine), is currently being examined in clinical trials [41,42,43], wherein its use avoids pathologies that typically include inflammation.…”

Targeting the Heme Oxygenase 1/Carbon Monoxide Pathway to Resolve Lung Hyper-Inflammation and Restore a Regulated Immune Response in Cystic Fibrosis

“…PP-007 is also PEGylated, which ensures stability and prolongs retention of the molecules in the circulation. PP-007 is being studied for several clinical situations to treat hypoxia and/or inflammation, including sickle cell disease (SCD), reperfusion injury, and cerebral hemorrhage (Misra et al, 2014;Abuchowski, 2016;Abuchowski, 2017;Dhar et al, 2017;Misra et al, 2017;Abu Jawdeh et al, 2018). PP-007 is safe in a phase I clinical trials in both healthy controls and patients with SCD.…”